US Patent

US9089587 — Treatment of papulopustular rosacea with ivermectin

Method of Use · Assigned to Galderma SA · Expires 2034-03-13 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating papulopustular rosacea by topically applying a composition containing ivermectin to an affected skin area.

USPTO Abstract

Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.

Drugs covered by this patent

Stromectol (ivermectin) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1631`	—	Stromectol

Patent Metadata

Patent number: US9089587
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Galderma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.